Why the study?
Cardiotoxicity is a major adverse effect of trastuzumab, and early prediction remains a significant clinical problem.
Does deceleration capacity of heart rate predict trastuzumab-related cardiotoxicity in patients with HER2-positive breast cancer?
Does deceleration capacity of heart rate predict trastuzumab-related cardiotoxicity in patients with HER2-positive breast cancer?
Deceleration capacity of heart rate is a stronger predictor of trastuzumab-related cardiotoxicity than baseline LVEF and HRV in patients with HER2-positive breast cancer.
Answers are grounded in this paper and cite their sources.
May aid trastuzumab cardiotoxicity risk stratification beyond LVEF; hypothesis-generating and should not yet change practice.
WHAT IS KNOWN AND OBJECTIVES: Trastuzumab is the standard choice for anti-human epidermal growth factor receptor 2 (HER2) therapy. Cardiotoxicity is one of the main adverse effects of trastuzumab. How to early predict trastuzumab-related cardiotoxicity remains a significant problem in clinical practice. The deceleration capacity of the heart rate (DC) has been shown to be a powerful predictor of adverse outcomes in various heart diseases. In the study, the role of DC in early predicting trastuzumab-related cardiotoxicity was investigated. METHODS: A total of 150 patients were prospectively investigated the clinical value of the DC in predicting trastuzumab-related cardiotoxicity in patients with HER2-positive breast cancer treated with trastuzumab at Guangxi Medical University Cancer Hospital from June 2015 to June 2017. DC, mean heart rate and heart rate variability (HRV) indices, including the standard deviation of all normal RR intervals (SDNN) and the square root of the mean of the squared differences between adjacent normal RR intervals (RMSSD), were assessed before treatment, and the left ventricular ejection fraction (LVEF) was regularly monitored for 2 years (before, during and after treatment) to evaluate cardiotoxicity. RESULTS: Among 150 eligible patients, 28 (18.7%) developed cardiotoxicity. Patients with cardiotoxicity were older (P < .05), higher anthracycline dose (P < .001) and had lower RMSSD (P < .05), SDNN, DC and baseline LVEF (P < .001), than patients without cardiotoxicity. Logistic regression analysis revealed lower DC, lower baseline LVEF and higher anthracycline dose were independent risk factors of trastuzumab-related cardiotoxicity. Receiver operating characteristic (ROC) curve analysis revealed a greater area under the curve for DC than for the baseline LVEF in predicting cardiotoxicity (0.88 vs 0.77, P = .032). Additionally, DC had higher sensitivity (78.6% vs 67.9%) and specificity (83.6% vs 77.9%) in predicting cardiotoxicity than the baseline LVEF. Linear regression analysis showed among patients who developed cardiotoxicity, lower DC was associated with an earlier onset (P < .01). WHAT IS NEW AND CONCLUSION: The present study found that DC was a stronger predictor of trastuzumab-related cardiotoxicity development than the baseline LVEF and HRV. Linear regression analysis showed among patients who developed cardiotoxicity, lower DC was associated with an earlier onset. DC should be a potential clinical indicator for the early prediction of trastuzumab-related cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Feng et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: